Search for facilities
To complete a search, you must enter a value in one of the fields

Human samples processing laboratory

GINYS-IRSICAIXA-002
Eulàlia Grau
Responsable de servei
egrau@irsicaixa.es | 934656374 ext 204 | ORCID | PRC page
FACILITY WEBSITE
The Sample Processing and Storage Service, in operation since 1993, supports scientific research in the biomedical field by processing and storing samples for use in both basic and clinical research. The team has over 15 years experience in the isolation and storage of PBMCs, plasma, serum, urine, faeces, semen, vaginal fluid, biopsy material, etc. Some 350 samples are processed monthly. The service has its own SOPs but adapts to the sample processing and storage protocols of sponsors for multicentre studies and to particular quality control and variable recording requirements.

Services

Processing of human specimens:
–  Isolation of PBMCs
–  Processing and aliquoting of plasma, serum, whole blood, urine, feces, saliva, among others
 
Storage of samples:
–   In -80ºC freezers
–   In nitrogen tanks (liquid phase and vapor phase)
 
Management of sample repositories:
–   Samples’ ins and outs registration into a Database
–   Registration of quality variables related to samples
–   Preparation of aliquots deliveries or shipments to researchers
–   Management of national and international shipments of samples
 
Participation in Clinical Trials:
–   Adaptation of processing protocols to the needs of the sponsor
–   Participation in quality controls for the processing of PBMCs
–   Completion and custody of the study documentation
–   Custody of samples
–   Management of national and international shipments of samples

Equipment

Its biosafety level 2 (BSL-2) and 3 (BSL-3) laboratories are equipped to ensure proper processing, transformation and storage of a wide variety of biological samples. The facilities also include various cryobiology rooms equipped with ultra-low freezers (-80ºC) and tanks of liquid nitrogen (-196ºC), permanently monitored through computerized recording and remote alarm systems.
 
EQUIPMENT
– Class II Biosafety Cabins
– Centrifuges with high capacity swinging bucket rotor
– Refrigerated centrifuges with swinging bucket rotor
– Microcentrifuges with fixed angle rotor
– NucleoCounter® NC3000TM automatic cell counters
– Pipette controllers
– Micropipettes
– – 20ºC /- 30ºC freezers
– – 80ºC ultrafreezers
– Liquid phase and vapor phase nitrogen containers
– Remote monitoring and temperature recording system for cold equipment

Staff

Responsable de Servei
Eulàlia Grau | egrau@irsicaixa.es | 934656374 ext 204 | ORCID | PRC Page
Equip tècnic de laboratori
Rafaela Ayen | rayen@irsicaixa.es | 934656374
Lucía Gómez | lgomez@irsicaixa.es | 934656374
Cristina Ramirez | cramirez@irsicaixa.es | 934656374
Mireia Martínez | mmartinezg@irsicaixa.es | 934656374

Publications

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification
Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. PMID: 23392458
DOI: AI.0b013e318289439a.
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
Trigueros M, Pradenas E, Palacín D, Muñoz-López F, Ávila-Nieto C, Trinité B, Bonet-Simó JM, Isnard M, Moreno N, Marfil S, Rovirosa C, Puig T, Grau E, Chamorro A, Martinez A, Toledo R, Font M, Ara J, Carrillo J, Mateu L, Blanco J, Clotet B, Prat N, Massanella M; CoronAVI@S and the KING cohort extension studies.
Age Ageing. 2022 May 1;51(5):afac101.
DOI: geing/afac101.
ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression
Ballana E, Senserrich J, Pauls E, Faner R, Mercader JM, Uyttebroeck F, Palou E, Mena MP, Grau E, Clotet B, Ruiz L, Telenti A, Ciuffi A, Esté JA.
Clin Infect Dis. 2010 Apr 1;50(7):1022-32. PMID: 20192730
DOI: 51114.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
Abella E, Trigueros M, Pradenas E, Muñoz-Lopez F, Garcia-Pallarols F, Ben Azaiz Ben Lahsen R, Trinité B, Urrea V, Marfil S, Rovirosa C, Puig T, Grau E, Chamorro A, Toledo R, Font M, Palacín D, Lopez-Segui F, Carrillo J, Prat N, Mateu L, Clotet B, Blanco J, Massanella M; VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies.
Life Sci Alliance. 2022 Aug 12;5(12):e202201479
DOI: lsa.202201479.
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group.
Lancet Respir Med. 2022 Mar;10(3):278-288. Epub 2022 Feb 9. PMID: 35150610 Free PMC article. Clinical Trial.
DOI: 2213-2600(21)00545-2.
Small form factor flow virometer for SARS-CoV-2
Hussain R, Ongaro AE, Rodriguez de la Concepción ML, Wajs E, Riveira-Muñoz E, Ballana E, Blanco J, Toledo R, Chamorro A, Massanella M, Mateu L, Grau E, Clotet B, Carrillo J, Pruneri V.
Biomed Opt Express. 2022 Feb 22;13(3):1609-1619.
DOI: OE.450212
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
Trinité B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarrés-Freixas F, Ortiz R, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Lepore R, Izquierdo-Useros N, Trujillo G, Trapé J, González-Fernández C, Flor A, Pérez-Vidal R, Toledo R, Chamorro A, Paredes R, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Blanco J.
Viruses. 2021 Jun 12;13(6):1135. PMID: 34204754
DOI: 13061135
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B; BCN-PEP-CoV2 Research Group.
N Engl J Med. 2021 Feb 4;384(5):417-427. Epub 2020 Nov 24. PMID: 33289973 Free PMC article. Clinical Trial.
DOI: EJMoa2021801
Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional study
Lladós G, Massanella M, Coll-Fernández R, Rodríguez R, Hernández E, Lucente G, López C, Loste C, Santos JR, España-Cueto S, Nevot M, Muñoz-López F, Silva-Arrieta S, Brander C, Durà MJ, Cuadras P, Bechini J, Tenesa M, Martinez-Piñeiro A, Herrero C, Chamorro A, Garcia A, Grau E, Clotet B, Paredes R, Mateu L; Germans Trias Long-COVID Unit group.
Clin Microbiol Infect. 2023 Nov 19:S1198-743X(23)00565-7. PMID: 37984511
DOI: 10.1016/j.cmi.2023.11.007
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
Pradenas E, Marfil S, Urrea V, Trigueros M, Pidkova T, Pons-Grífols A, Ortiz R, Rovirosa C, Tarrés-Freixas F, Aguilar-Gurrieri C, Toledo R, Chamorro A, Noguera-Julian M, Mateu L, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Trinité B, Blanco J.
iScience. 2023 Apr 21;26(4):106457. Epub 2023 Mar 20. PMID: 36999095
DOI: 10.1016/j.isci.2023.106457
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, Rodríguez de la Concepción ML, Ávila-Nieto C, Aguilar-Gurrieri C, Barajas A, Ortiz R, Paredes R, Mateu L, Valencia A, Guallar V, Ruiz L, Grau E, Massanella M, Puig J, Chamorro A, Izquierdo-Useros N, Segalés J, Clotet B, Carrillo J, Vergara-Alert J, Blanco J.
Sci Rep. 2021 Jan 28;11(1):2608. PMID: 33510275
DOI: 10.1038/s41598-021-81862-9
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients
Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, García E, Moltó J, Grassi J, Clotet B.
Antimicrob Agents Chemother. 2005 May;49(5):1907-14. PMID: 15855513
DOI: 10.1128/AAC.49.5.1907-1914.2005

INSTITUTE

IrsiCaixa - Institut de Recerca de la Sida

Campus Can Ruti
Hosp. Germans Trias i Pujol
Carretera Canyet, s/n

08916 Badalona http://www.irsicaixa.es/es

DOMAINS RIS3CAT

  • Education and knowledge generation system
  • Industrial system
  • Socio-sanitary system

CATEGORIES

  • CLINICAL TRIALS
  • COLLECTIONS
    • Other collections
  • TECHNOLOGICAL EQUIPMENT
    • Other specializated laboratories

RATES AND ACCESS

Tarifes_GINYS-IRSICAIXA-002_1-2.pdf
Availability Level: Medium
Access Procedures:
Open. Contact the person responsible for the service via email.

QUALITY CONTROL

Biosafety Level 3 (or NBS3)
It is already considered a high level of containment, it is found in some clinical and diagnostic laboratories, and some university and government research laboratories, in which work is done with exotic agents or that can cause serious damage and potentially fatal as a result of inhalation or exposure to them (some haemorrhagic fever viruses, but not filoviruses, many arboviruses and bacteria with Francisella tularensis, Coxiella burnetii, SARS-CoV-2 (COVID-19), etc.)
Website link
Status: Active
Biosafety Level 2 (or NBS2)
Moderate risk agents are handled for staff and the environment, so they are the most common in clinical, hospital and academic research.
Website link
Status: Active
GMO Type 3 – Moderate Risk
USE CONFINED WITH GMO TYPE 3 (Moderate Risk) IN SPAIN In accordance with the provisions of article 5 of Law 9/2003, confined use is understood to be any activity for which the genetic material of an organism is modified or for which it, as modified, is cultivated, stored, used. , transport, destruction or disposal, provided that containment measures are used in carrying out these activities, in order to limit contact with the population and the environment.
Website link
Status: Active
GMO Type 2 – Low risk
USE CONFINED WITH GMO TYPE 2 (Low Risk) IN SPAIN  In accordance with the provisions of article 5 of Law 9/2003, confined use is understood to be any activity for which the genetic material of an organism is modified or for which it, as modified, is cultivated, stored, used. , transport, destruction or disposal, provided that containment measures are used in carrying out these activities, in order to limit contact with the population and the environment.
Website link
Status: Active
SOP
Standard operating procedure (SOP or PNTs) Manufacture of sanitary product to measure regulated by the Regulation (EU) 2017/745 of sanitary product
Status: Active
CERCA - Ginys